REPL Replimune Group Inc

Price (delayed)

$35.44

Market cap

$1.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.75

Enterprise value

$1.36B

Sector: Healthcare
Industry: Biotechnology

Highlights

Replimune Group's quick ratio has soared by 190% YoY and by 97% from the previous quarter
The company's equity has surged by 161% YoY and by 97% QoQ
The net income has plunged by 73% YoY and by 8% from the previous quarter
The company's EPS fell by 39% YoY

Key stats

What are the main financial stats of REPL
Market
Shares outstanding
46.49M
Market cap
$1.65B
Enterprise value
$1.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$71.77M
EBITDA
-$70.21M
Free cash flow
-$59.48M
Per share
EPS
-$1.75
Free cash flow per share
-$1.2
Book value per share
$11.23
Revenue per share
$0
TBVPS
$11.32
Balance sheet
Total assets
$559.2M
Total liabilities
$43M
Debt
$33.42M
Equity
$516.2M
Working capital
$486.41M
Liquidity
Debt to equity
0.06
Current ratio
38.36
Quick ratio
38.18
Net debt/EBITDA
4.17
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-20.9%
Return on equity
-24.3%
Return on invested capital
-28.4%
Return on capital employed
-13.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
1.11%
1 week
4.27%
1 month
18.29%
1 year
74.84%
YTD
-7.1%
QTD
16.16%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$74.16M
Net income
-$75.16M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 73% YoY and by 8% from the previous quarter
The operating income has dropped by 56% year-on-year and by 5% since the previous quarter

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
3.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 39% YoY
The company's equity has surged by 161% YoY and by 97% QoQ

Efficiency

How efficient is Replimune Group business performance
REPL's ROE is up by 20% QoQ and by 18% YoY
Replimune Group's return on assets has increased by 16% YoY and by 15% QoQ
Replimune Group's return on invested capital has increased by 11% YoY but it has decreased by 4% QoQ

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
Replimune Group's quick ratio has soared by 190% YoY and by 97% from the previous quarter
REPL's current ratio has soared by 186% YoY and by 97% QoQ
Replimune Group's debt is 94% less than its equity
The company's equity has surged by 161% YoY and by 97% QoQ
The debt to equity has dropped by 71% year-on-year and by 65% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.